Predictive Historical Income Statement
| POAI Stock | USD 0.78 0.02 2.50% |
Historical analysis of Predictive Oncology income statement accounts such as Other Operating Expenses of 9.6 M, Total Operating Expenses of 9.3 M, Income Tax Expense of 3.8 or Total Revenue of 899.7 K can show how well Predictive Oncology performed in making a profits. Evaluating Predictive Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Predictive Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Predictive Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Predictive Oncology is a good buy for the upcoming year.
Predictive |
About Predictive Income Statement Analysis
Predictive Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Predictive Oncology shareholders. The income statement also shows Predictive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Predictive Oncology Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Predictive Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Depreciation And Amortization is increasing as compared to previous years. The Predictive Oncology's current Interest Expense is estimated to increase to about 12.9 M, while Selling General Administrative is projected to decrease to under 7.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 933.7K | 1.0M | 1.1M | 575.4K | Total Revenue | 1.4M | 1.5M | 1.8M | 899.7K |
Predictive Oncology income statement Correlations
Click cells to compare fundamentals
Predictive Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Predictive Oncology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 8.9M | 1.0M | 1.3M | 1.3M | 739.3K | 954.9K | |
| Selling General Administrative | 9.8M | 10.4M | 10.9M | 11.1M | 9.4M | 7.1M | |
| Selling And Marketing Expenses | 1.9M | 584.9K | 774.5K | 1.4M | 1.5M | 913.9K | |
| Other Operating Expenses | 15.2M | 13.7M | 14.9M | 16.8M | 15.7M | 9.6M | |
| Operating Income | (13.8M) | (666.3K) | (13.5M) | (15.3M) | (13.9M) | (13.2M) | |
| Ebit | (13.8M) | (12.5M) | (13.5M) | (15.3M) | (13.9M) | (13.2M) | |
| Ebitda | (4.9M) | (11.5M) | (12.1M) | (14.0M) | (13.2M) | (12.5M) | |
| Total Operating Expenses | 14.7M | 13.3M | 14.4M | 16.3M | 15.1M | 9.3M | |
| Net Income | (27.6M) | (37.7M) | (19.7M) | (36.2M) | (14.0M) | (14.7M) | |
| Income Tax Expense | 8.2M | 11.8M | (661.7K) | 10.5M | 4.0 | 3.8 | |
| Total Revenue | 1.4M | 1.3M | 1.4M | 1.5M | 1.8M | 899.7K | |
| Gross Profit | 879.8K | 805.1K | 933.7K | 1.0M | 1.1M | 575.4K | |
| Cost Of Revenue | 531.8K | 447.2K | 487.0K | 505.1K | 634.8K | 324.3K | |
| Income Before Tax | (19.4M) | (25.9M) | (20.3M) | (25.7M) | (14.0M) | (14.7M) | |
| Total Other Income Expense Net | (5.6M) | (13.4M) | (6.8M) | (10.5M) | (62.6K) | (65.8K) | |
| Research Development | 3.0M | 2.4M | 315.9K | 320.3K | 188.3K | 178.9K | |
| Net Income From Continuing Ops | (19.4M) | (25.9M) | (19.7M) | (25.7M) | (18.4M) | (19.3M) | |
| Net Income Applicable To Common Shares | (19.7M) | (26.4M) | (19.7M) | (25.7M) | (23.2M) | (24.3M) | |
| Reconciled Depreciation | 704.9K | 1.0M | 1.3M | 1.3M | 913.7K | 866.8K |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.